New hope for advanced liver cancer: drug combo trial shows promise
NCT ID NCT06519721
First seen Apr 25, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This study tests whether combining two drugs, lenvatinib and VIC-1911, can safely shrink tumors and slow cancer growth in people with advanced liver cancer. About 12 adults aged 18-75 with stage C liver cancer and good liver function are taking part. The goal is to see how well the treatment works and how long it keeps the cancer under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.